GlassScriptPhysician profile
Jeffrey R Greene
NPI 1124070651
$3,153.32
in general payments reported to CMS, 2019-2025
29 companies · $795 in 2025
The $795 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2021: $40.03 · 2022: $147 · 2023: $880 · 2024: $827 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $706.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $451.23 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $287.96 | 2022-2025 | |
| Abbott Laboratories | $278.25 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Astrazeneca Pharmaceuticals LP | $219.40 | 2019-2025 | Airsupra |
| Pfizer INC. | $154.95 | 2019-2025 | |
| Astellas Pharma US INC | $115.35 | 2022-2025 | Veozah |
| Djo, LLC | $108.00 | 2024 | Procare |
| Exact Sciences Corporation | $102.85 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $85.46 | 2019-2024 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.59 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $71.90 | 2023-2024 | Rexulti, Nuedexta |
| Amgen INC. | $58.77 | 2022-2025 | Repatha, Otezla, Evenity |
| Genentech USA, INC. | $54.98 | 2019 | |
| Xeris Pharmaceuticals, INC. | $50.81 | 2022-2023 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.05 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $35.19 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $32.24 | 2019-2025 | Heplisav-B |
| Corcept Therapeutics | $31.53 | 2025 | Korlym |
| Phadia US INC. | $31.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.26 | 2019 | |
| Shire North American Group INC | $22.30 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.00 | 2025 | Caplyta |
| Gilead Sciences, INC. | $17.08 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.02 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $16.33 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.89 | 2022 | |
| Aytu Biopharma, INC. | $13.49 | 2019 | |
| Merck Sharp & Dohme LLC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.